1. Home
  2. LPCN vs SYNX Comparison

LPCN vs SYNX Comparison

Compare LPCN & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPCN
  • SYNX
  • Stock Information
  • Founded
  • LPCN 1997
  • SYNX 2005
  • Country
  • LPCN United States
  • SYNX Israel
  • Employees
  • LPCN N/A
  • SYNX N/A
  • Industry
  • LPCN Biotechnology: Pharmaceutical Preparations
  • SYNX
  • Sector
  • LPCN Health Care
  • SYNX
  • Exchange
  • LPCN Nasdaq
  • SYNX Nasdaq
  • Market Cap
  • LPCN 16.1M
  • SYNX 13.7M
  • IPO Year
  • LPCN N/A
  • SYNX 2024
  • Fundamental
  • Price
  • LPCN $3.29
  • SYNX $1.74
  • Analyst Decision
  • LPCN Strong Buy
  • SYNX
  • Analyst Count
  • LPCN 2
  • SYNX 0
  • Target Price
  • LPCN $9.00
  • SYNX N/A
  • AVG Volume (30 Days)
  • LPCN 59.4K
  • SYNX 127.8K
  • Earning Date
  • LPCN 08-07-2025
  • SYNX 05-14-2025
  • Dividend Yield
  • LPCN N/A
  • SYNX N/A
  • EPS Growth
  • LPCN N/A
  • SYNX N/A
  • EPS
  • LPCN N/A
  • SYNX N/A
  • Revenue
  • LPCN $3,674,834.00
  • SYNX $9,094,000.00
  • Revenue This Year
  • LPCN N/A
  • SYNX $32.35
  • Revenue Next Year
  • LPCN N/A
  • SYNX N/A
  • P/E Ratio
  • LPCN N/A
  • SYNX N/A
  • Revenue Growth
  • LPCN N/A
  • SYNX 19.14
  • 52 Week Low
  • LPCN $2.68
  • SYNX $1.65
  • 52 Week High
  • LPCN $8.71
  • SYNX $6.49
  • Technical
  • Relative Strength Index (RSI)
  • LPCN 51.52
  • SYNX 48.15
  • Support Level
  • LPCN $3.13
  • SYNX $1.67
  • Resistance Level
  • LPCN $3.53
  • SYNX $1.91
  • Average True Range (ATR)
  • LPCN 0.24
  • SYNX 0.20
  • MACD
  • LPCN 0.01
  • SYNX 0.02
  • Stochastic Oscillator
  • LPCN 48.33
  • SYNX 22.21

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

Share on Social Networks: